Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIMMUNAGE: COVID-19 Vaccine Response by Age and History
NCT05047718Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran, elasomeran in coronavirus disease 2019 (COVID-19), sponsored by CHU Saint-Etienne. Started Oct 2021; status: completed.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05047718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047718.